Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Tale Of Two Giants; Tracking India And China’s Rise In The Pharmaceutical Market

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - The nature of business relationships between multinational pharma companies and Indian and Chinese firms varies significantly, according to a recent study released by the Ewing Marion Kauffman Foundation

You may also be interested in...



Ranbaxy Files For Phase I Trial On First Compound From GSK Deal

MUMBAI - A year after identifying a potential compound targeted at respiratory inflammation for joint development with GSK Pharma, India's largest drug maker, Ranbaxy has submitted an application to the Drug Controller General of India to initiate Phase I trials

Ranbaxy Files For Phase I Trial On First Compound From GSK Deal

MUMBAI - A year after identifying a potential compound targeted at respiratory inflammation for joint development with GSK Pharma, India's largest drug maker, Ranbaxy has submitted an application to the Drug Controller General of India to initiate Phase I trials

GNI And EpiCept Ink Development Deal For Anti-Viral Hepatitis B Drug

SHANGHAI - GNI and EpiCept have entered into an agreement that will see the latter develop a new anti-viral hepatitis B drug, EP1013, in Asia, Australia and New Zealand

Related Content

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel